title: BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta.
abstract: Of 20 fibroblast cell strains from patients with osteogenesis imperfecta (OI), a disease caused by mutations in the genes encoding type I procollagen, three had increased synthesis of BiP (GRP78), an hsp70-related, endoplasmic reticulum-resident protein. All three strains carry unique mutations in pro alpha 1(I) chains which impair type I procollagen chain association. Immunoprecipitation and pulse-chase experiments show that BiP (immunoglobulin heavy chain-binding protein) stably binds pro alpha 1(I) chains in these three cell strains after a brief lag. Ascorbate, which increases procollagen synthesis, increases BiP synthesis and content in these three strains and not in the others. In one of these three strains, BiP content is constitutively elevated prior to ascorbate treatment, and BiP is less inducible. This strain also has relatively high levels of synthesis and content of GRP94, another endoplasmic reticulum-resident stress protein. Pretreating each of the three cell strains to increase their BiP content reduces subsequent ascorbate-mediated BiP induction. BiP synthesis in the 17 other OI strains examined, which had a variety of type I procollagen mutations, was normal. These results suggest that BiP is induced by and binds procollagen with specific types of mutations: ones in the carboxyl-terminal propeptide that interfere with chain association. The recognition by BiP of such procollagen in OI cell strains shows that BiP plays a role in the physiological response to the production of some disease-producing abnormal proteins.
authors.affiliation: Department of Pathology, University of Washington, Seattle 98195.
authors.forename: S D
authors.initials: SD
authors.lastname: Chessler
authors.forename: P H
authors.initials: PH
authors.lastname: Byers
mesh_terms: D015082:2,2'-Dipyridyl / Q000494:pharmacology; D000595:Amino Acid Sequence; D001205:Ascorbic Acid / Q000494:pharmacology; D002352:Carrier Proteins / Q000096:biosynthesis / Q000302:isolation & purification / Q000378:metabolism*; D002478:Cells, Cultured; D000091342:Endoplasmic Reticulum Chaperone BiP; D005260:Female; D005313:Fetal Death; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007700:Kinetics; D046911:Macromolecular Substances; D018832:Molecular Chaperones; D008970:Molecular Weight; D010013:Osteogenesis Imperfecta / Q000235:genetics* / Q000378:metabolism*; D017354:Point Mutation; D011347:Procollagen / Q000096:biosynthesis / Q000302:isolation & purification / Q000378:metabolism*; D011485:Protein Binding; D012867:Skin / Q000378:metabolism*
chemical_list: D002352:Carrier Proteins; D000091342:Endoplasmic Reticulum Chaperone BiP; C000717247:HSPA5 protein, human; D006360:Heat-Shock Proteins; D046911:Macromolecular Substances; D018832:Molecular Chaperones; D011347:Procollagen; D015082:2,2'-Dipyridyl; D001205:Ascorbic Acid